Rothwell Figg

Earlier this month, in University of Strathclyde v. Clear-Vu Lighting LLC, the Court of Appeals for the Federal Circuit (“the CAFC”) reversed a decision by the Patent Trial and Appeal Board (“the Board”) that found claims 1-4 of the University
Continue Reading Federal Circuit Reaffirms Obviousness Standard by Reversing PTAB in University of Strathclyde v. Clear-Vu Lighting

Introduction

Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each year to advance knowledge across the gamut of Arts, Humanities, and Science, Technology, Engineering, and Mathematics (STEM) fields. That R&D
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students

Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in vivo gene therapies for rare diseases using Mammoth’s ultra-small CRISPR systems.

Over the past couple of years, Mammoth Biosciences, the
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems

On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV) capsids for gene therapies.

Voyager is a Massachusetts-based company developing AAV-based gene therapies.  The
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million

Last month, in the case In re: MaxPower Semiconductor, Inc., the Court of Appeals for the Federal Circuit (“the CAFC”) dismissed an appeal by MaxPower Semiconductor, Inc. (“MaxPower”) of four determinations to institute inter partes review (“IPR”) of four of
Continue Reading Judge O’Malley Dissents from the Majority on the Enforceability of Arbitration Agreements in IPR Proceedings